SCHEMBL1984083

SCHEMBL1984083

CCc1c(C(=O)O)nn(-c2ccc(Cl)cc2)c1-c1cc(C)co1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.42
HIF1A Q16665 1/20 0.42
KMT2A Q03164 4/20 0.42
POLB P06746 3/20 0.42
MEN1 O00255 3/20 0.42
RECQL P46063 2/20 0.42
CACNA1B Q00975 1/20 0.42
APBA1 Q02410 1/20 0.42
MCL1 Q07820 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
PPP1CA P62136 1/20 0.41
PTGS2 P35354 2/20 0.40
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 4/20 0.38
MAPT P10636 3/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1985208 0.91 CYP1A2 (0.44) CYP1A2HIF1AKMT2APOLBMEN1
SCHEMBL1985791 0.88 CYP1A2 (0.42) CYP1A2HIF1AKMT2APOLBMEN1
SCHEMBL1987723 0.87 TP53 (0.45) KMT2AMEN1RECQLTDP1L3MBTL1
SCHEMBL1989077 0.86 CYP1A2 (0.46) CYP1A2HIF1AKMT2APOLBMEN1
SCHEMBL1985182 0.86 CNR2 (0.47) LMNACNR1
SCHEMBL1986862 0.82 CYP1A2 (0.44) CYP1A2HIF1AKMT2APOLBMEN1
SCHEMBL1988653 0.82 TP53 (0.44) CYP1A2RECQLL3MBTL1ALDH1A1MAPT
SCHEMBL1985146 0.81 CYP1A2 (0.45) CYP1A2HIF1AKMT2APOLBMEN1
SCHEMBL1987766 0.79 CYP1A2 (0.43) CYP1A2HIF1AKMT2APOLBMEN1
SCHEMBL1984324 0.78 CYP1A2 (0.46) CYP1A2HIF1AKMT2APOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1602656-A1 PYRAZOLE DERIVATIVES HAVING AFFINITY FOR CB1 AND/OR CB2 RECEPTORS NEUROSCIENZE PHARMANESS S.C. a R.L. (IT) 2005-12-07 EP claimed
US-20050261281-A1 Pharmaceutical compounds MIDCAP FUNDING III, LLC 2005-11-24 US claimed
US-8227620-B2 Pharmaceutical compounds NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) 2012-07-24 US disclosed
EP-1602656-B1 PYRAZOLE DERIVATIVES HAVING AFFINITY FOR CB1 AND/OR CB2 RECEPTORS NEUROSCIENZE PHARMANESS S C A R L (IT) 2011-06-29 EP disclosed
US-20100105896-A1 PHARMACEUTICAL COMPOUNDS Neuroscienze Pharmaness S.C.a.R.I. (IT) 2010-04-29 US disclosed
US-7659407-B2 pyrazole derivatives having affinity for cannabinoidergic CB1 and/or CB2 receptors; immune disorders, osteoporosis, renal ischemia, inflammation,transplant rejection; 5-(5-Chloro-thiofen-2-yl)-1-(4-methoxy-phenyl)-4-methyl-1H-pyrazol-3-carboxylic acid Neuroscienze Pharmaness S.C.a.R.I. (IT) 2010-02-09 US disclosed
EP-1602656-A1 PYRAZOLE DERIVATIVES HAVING AFFINITY FOR CB1 AND/OR CB2 RECEPTORS NEUROSCIENZE PHARMANESS S.C. a R.L. (IT) 2005-12-07 EP disclosed
US-20050261281-A1 Pharmaceutical compounds MIDCAP FUNDING III, LLC 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105896-A1 PHARMACEUTICAL COMPOUNDS CNR1, CNR2, OPRD1 CYP1A2 129/4885HIF1A 2240/4885KMT2A 1529/4885
US-20050261281-A1 Pharmaceutical compounds CNR1, CNR2, OPRD1 CYP1A2 207/4885HIF1A 1502/4885KMT2A 872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.